• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:04:31 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OBSV alert in real time by email
    SC 13G/A 1 ss192042_sc13ga.htm AMENDMENT NO. 2

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     (Amendment No. 2)*



     

    ObsEva SA
    (Name of Issuer)

     

     

    Common Stock
    (Title of Class of Securities)

     

     

    H5861P103
    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

       

     

      

    CUSIP No. H5861P103  SCHEDULE 13G Page 2 of 8 Pages

     

             
    1

    NAME OF REPORTING PERSONS

     

    OrbiMed Capital GP V LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.00%

    12

    TYPE OF REPORTING PERSON

     

    OO

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 3 of 8 Pages

     

             
    1

    NAME OF REPORTING PERSONS

     

    OrbiMed Advisors LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

       

     

      

    CUSIP No.  H5861P103  SCHEDULE 13G Page 4 of 8 Pages

     

    Item 1.   (a) Name of Issuer:

    ObsEva SA

        (b) Address of Issuer’s Principal Executive Offices:

    Chemin des Aulx, 12

    1228 Plan-les-Ouates

    Geneva, Switzerland

    Item 2.   (a) Name of Person Filing:

    OrbiMed Capital GP V LLC

    OrbiMed Advisors LLC

        (b) Address of Principal Business Office:

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

        (c) Citizenship:

    Please refer to Item 4 on each cover page for each Reporting Person.

        (d) Title of Class of Securities:

    Common Stock, Par Value $0.0001 Per Share

        (e) CUSIP No.:

    H5861P103

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 5 of 8 Pages

     

     

    Item 3.      

    OrbiMed Capital GP V LLC (“GP V”) is the general partner of OrbiMed Private Investments V, LP. OrbiMed Advisors LLC (“Advisors”) is an investment advisor in accordance with ss.240.13d-1(b)(1)(ii)(E) and Advisors is the managing member of GP V.

     

     

     

     

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 6 of 8 Pages

     

     

    Item 4. Ownership:

    Information with respect to the Reporting Person’s ownership as of December 31, 2020 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 7 of 8 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021

     

     

      OrbiMed Advisors LLC
           
      By: /s/ Jonathan T. Silverstein  
        Name:  Jonathan T. Silverstein
        Title:  Member
           
      By: /s/ Sven H. Borho  
        Name:  Sven H. Borho
        Title:  Member
           
      By: /s/ Carl L. Gordon  
        Name:  Carl L. Gordon
        Title:  Member
           
           
     

    OrbiMed Capital GP V LLC

    By: OrbiMed Advisors LLC, its Managing Member

           
      By: /s/ Jonathan T. Silverstein  
        Name:  Jonathan T. Silverstein
        Title:  Member of OrbiMed Advisors LLC
           
      By: /s/ Sven H. Borho  
        Name:  Sven H. Borho
        Title:  Member of OrbiMed Advisors LLC
           
      By: /s/ Carl L. Gordon  
        Name:  Carl L. Gordon
        Title:  Member of OrbiMed Advisors LLC
           
             

     

     

     

    Get the next $OBSV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OBSV

    DatePrice TargetRatingAnalyst
    8/30/2022Buy → Neutral
    H.C. Wainwright
    6/3/2022$6.00Overweight
    Cantor Fitzgerald
    4/26/2022$12.00Buy
    Canaccord Genuity
    3/28/2022$12.00Buy
    Aegis Capital
    11/29/2021$17.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OBSV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ObsEva Files Year End 2022 Financial Statements

      ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20

      3/31/23 4:01:00 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd

      3/15/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

      3/13/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ObsEva downgraded by H.C. Wainwright

      H.C. Wainwright downgraded ObsEva from Buy to Neutral

      8/30/22 7:29:47 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ObsEva with a new price target

      Cantor Fitzgerald initiated coverage of ObsEva with a rating of Overweight and set a new price target of $6.00

      6/3/22 7:29:31 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on ObsEva with a new price target

      Canaccord Genuity initiated coverage of ObsEva with a rating of Buy and set a new price target of $12.00

      4/26/22 6:26:53 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    SEC Filings

    See more
    • SEC Form 15-12G filed by ObsEva SA

      15-12G - ObsEva SA (0001685316) (Filer)

      4/26/23 7:00:50 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - ObsEva SA (0001685316) (Filer)

      4/11/23 4:01:29 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by ObsEva SA

      10-K - ObsEva SA (0001685316) (Filer)

      3/31/23 4:01:50 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Loumaye Ernest

      4 - ObsEva SA (0001685316) (Issuer)

      4/11/23 4:02:23 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Loumaye Ernest bought $440,000 worth of shares (4,000,000 units at $0.11), increasing direct ownership by 200% to 6,000,000 units

      4 - ObsEva SA (0001685316) (Issuer)

      3/2/23 4:16:42 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brown William Michael

      4 - ObsEva SA (0001685316) (Issuer)

      2/24/23 4:50:38 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Leadership Updates

    Live Leadership Updates

    See more
    • ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

      3/13/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

      GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting. "We could not be more pleased, or fortunate, to have

      5/19/22 7:05:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra

      5/2/22 7:00:00 AM ET
      $EVFM
      $OBSV
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Financials

    Live finance-specific insights

    See more
    • ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

      -Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States- Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange                 GENEVA, Switzerland – May 17, 2022 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharma

      5/17/22 7:00:00 AM ET
      $OBSV
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

      GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate via telephone by dialling (877) 300-8521 (domestic) or +1 (412) 317-6026 (international) and using conference ID 10166576. The webcast can be accessed live here and will also be accessible under "Events Calendar" in the investors section of ObsEva's website. The webcast will be archived on the company

      5/12/22 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

      -Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT demonstrated statistically significant improvement for dysmenorrhea versus placebo and showed improvement but did not meet the co-primary objective of reduction in non-menstrual pelvic pain at 3 months; also showed improvement in sec

      1/6/22 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by ObsEva SA

      SC 13D - ObsEva SA (0001685316) (Subject)

      4/17/23 5:00:00 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ObsEva SA (Amendment)

      SC 13G/A - ObsEva SA (0001685316) (Subject)

      2/14/23 4:18:58 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - ObsEva SA (0001685316) (Subject)

      3/4/21 6:13:21 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care